Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer

• M. I. Martínez-Fernández ^[1] ; J. L. Pérez Gracia ^[1] ; I. Gil-Bazo ^[1] ; R. Martínez-Monge ^[1]
  1. [1] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 7, 2016, págs. 743-747
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To investigate whether bon e metastases-directed stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer (OPC).

    Methods and material OPC is usually managed with androgen deprivation therapy (ADT). Migration to castration-resistant prostate cancer will inevitably occur in the majority of these patients. There are several strategies aimed to delay the emergence of castration resistance including intermittent ADT, second generation antiandrogens (abiraterone, enzalutamide) or metastases-directed SBRT. The present report describes two cases of patients with OPC that received SBRT 24 Gy/3Rx to the solitary bony lesion after ADT failure.

    Results Both cases showed complete and durable biochemical response for 13 and 17 months, respectively.

    Conclusions SBRT can be used to delay the emergence of castration resistance and the need for systemic therapy when used after ADT failure.